H.C. Wainwright raised the firm’s price target on Nuvation Bio (NUVB) to $11 from $10 and keeps a Buy rating on the shares. The firm sees additional upside in taletrectinib.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.